Q3 EPS Estimate for Reviva Pharmaceuticals Lifted by Analyst

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) – Research analysts at Zacks Research increased their Q3 2026 earnings per share (EPS) estimates for Reviva Pharmaceuticals in a research report issued on Monday, August 17th. Zacks Research analyst J. Vandermosten now expects that the company will post earnings per share of ($0.40) for the quarter, up from their prior forecast of ($0.55). The consensus estimate for Reviva Pharmaceuticals’ current full-year earnings is ($2.96) per share. Zacks Research also issued estimates for Reviva Pharmaceuticals’ Q4 2026 earnings at ($0.41) EPS, FY2026 earnings at ($1.41) EPS and FY2028 earnings at ($0.67) EPS.

Reviva Pharmaceuticals (NASDAQ:RVPH) last announced its earnings results on Thursday, August 13th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.38) by $0.19.

Separately, Wall Street Zen upgraded shares of Reviva Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday, July 5th. Three investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $75.00.

Reviva Pharmaceuticals Trading Up 8.7%

Shares of RVPH stock opened at $0.50 on Thursday. Reviva Pharmaceuticals has a 12-month low of $0.26 and a 12-month high of $17.20. The business’s 50 day moving average is $0.55 and its two-hundred day moving average is $1.60. The company has a market capitalization of $6.55 million, a P/E ratio of -0.27 and a beta of 0.53.

Institutional Investors Weigh In On Reviva Pharmaceuticals

Hedge funds have recently modified their holdings of the company. Geode Capital Management LLC raised its stake in Reviva Pharmaceuticals by 6.9% during the second quarter. Geode Capital Management LLC now owns 448,202 shares of the company’s stock worth $171,000 after purchasing an additional 29,063 shares during the period. NewEdge Advisors LLC purchased a new stake in shares of Reviva Pharmaceuticals in the 1st quarter valued at approximately $58,000. XTX Topco Ltd increased its holdings in shares of Reviva Pharmaceuticals by 63.6% during the 4th quarter. XTX Topco Ltd now owns 164,291 shares of the company’s stock worth $46,000 after buying an additional 63,893 shares during the last quarter. Lido Advisors LLC acquired a new stake in shares of Reviva Pharmaceuticals during the 3rd quarter worth approximately $37,000. Finally, Millennium Management LLC raised its position in shares of Reviva Pharmaceuticals by 15.0% during the 3rd quarter. Millennium Management LLC now owns 1,711,221 shares of the company’s stock valued at $631,000 after buying an additional 223,178 shares during the period. Hedge funds and other institutional investors own 63.18% of the company’s stock.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals, Inc (NASDAQ: RVPH) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes.

The company’s core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings.